News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Professor Laurence Pearl awarded prestigious Novartis Medal and Prize
Professor Laurence Pearl, Head of the Division of Structural Biology, has been awarded the Novartis Medal and Prize by the Biochemical Society.
ICR thanks star fundraisers for their significant contributions to our research
Bowel cancer patient and fundraiser Tim Morgan and founder of The Chris Lucas Trust, Lynn Lucas, were thanked at the October meeting of the ICR's Discovery Club for their phenomenal fundraising efforts to support our research.
ICR responds to NICE decision on olaparib for women with advanced ovarian cancer
NICE has announced today, its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.
Climb of Life fundraising total hits £1 million
In its 12th year raising money for The Institute of Cancer Research, London, the Climb of Life has reached the tremendous milestone of raising over £1 million.
ICR welcomes TfL consultation on Sutton tram extension
The Institute of Cancer Research, London, has welcomed the opening of a formal planning consultation on new proposals to take the tram to Sutton station as a stepping stone towards extending the tram to The London Cancer Hub site.
Goodbye to one of our most inspirational teachers
Our students have thanked Professor Keith Jones for his support and dedication to training the next generation of cancer researchers as he retires from The Institute of Cancer Research, London.
ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer
Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.
ESMO 2018: Cancer trial shows treating the prostate directly with radiotherapy improves survival
Treating the prostate with radiotherapy alongside standard treatment led to a 11 per cent increase in survival for some men with advanced prostate cancer, according to a new study.
Fewer but larger radiation doses cause similarly low side-effects as conventional breast cancer radiotherapy
Women who received radiotherapy for early-stage breast cancer in fewer, larger doses experienced similarly low rates of late-onset side-effects as those receiving conventional treatment, results from a 10-year study show.
ESMO 2018: Major trial shows targeted drug – palbociclib – extends breast cancer survival
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.
The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer
The ICR strongly welcomes the news that talazoparib (trade name Talzenna) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.
New study discovers inhibitors of protein linked to the devastating childhood brain cancer DIPG
Scientists at The Institute of Cancer Research, London in collaboration with a team at the Structural Genomics Consortium in Oxford (SGC) have created a new series of compound that could form the basis for drugs that target the devastating childhood brain cancer diffuse intrinsic pontine glioma, or DIPG.
